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Background: Cystic fibrosis liver disease (CFLD) occurs in 37% of patients with CF. To date and to the best of our knowledge, there has
not been a documented case of hepatocellular carcinoma in association with cirrhosis and CF. Case report: A 32-year-old lady with cystic
fibrosis (CF) presented for her annual review. She had been diagnosed with CFLD since early adolescence. A routine ultrasound of her liver
revealed lesions consistent with hepatocellular carcinoma. This was confirmed on histology. She had no risk factors for hepatitis, and
thorough investigation revealed no other cause for her chronic liver disease. She was also found to be pregnant at the time of diagnosis. Her
tumour was considered too large for resection and liver transplantation and she was referred to a national centre for laser ablative therapy.
Conclusion: It is our concern that with the increased life expectancy of patients with CF and the chronic nature of CFLD that this may be an
increasingly recognised complication amongst the CF adult population. Therefore, we have changed our practice to more intense surveillance
of patients with established CFLD to incorporate biannual ultrasound imaging of the hepatic system and yearly serum concentration
measurements of alpha-fetoprotein.
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1. Case report aeruginosa at age 30. On referral to the regional adult CFA 32-year-old lady known to have cystic fibrosis (CF)
attended her annual review appointment at a regional adult
CF Centre. On routine ultrasound imaging of her liver, it
was noticed that she had a focal hepatic lesion. She was
therefore referred to the hepatology services.
Her CF was diagnosed in infancy when she presented
with abdominal problems and pneumonia. A sweat test
was performed which confirmed the diagnosis of CF. Her
genotype was found to be Delta F508 homozygote, the
most common mutation and one associated with a more
severe phenotype. Her CF was complicated by pancreatic
insufficiency and diabetes mellitus. She had surgery for
removal of an appendix when she was 12 and nasal
polypectomy when she was 26 years old. Her lung
function remained excellent throughout childhood, pre-
dicted at 89%. During her adolescence, she became colo-
nized with Staphylococcus aureus and then Pseudomonas1569-1993/$ - see front matter D 2004 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.jcf.2004.04.006
* Corresponding author.centre, at the age of 26, she had established CF liver
disease (CFLD) with her alkaline phosphatase (ALP) and
aspartate transaminase (AST) three times the upper limit of
normal. Biochemical liver disease had been diagnosed
since early adolescence with greater than twice normal
ALP since she was 13 years of age. Her first imaging of
the hepatic system occurred when she was transferred to
the regional adult CF clinic. At this time, an ultrasound
scan of the liver revealed findings in keeping with macro-
nodular cirrhosis and portal hypertension. Treatment was
therefore commenced with ursodeoxycholic acid at 600 mg
twice daily, and the liver function tests improved to just
above the upper limit of the normal range. Ursodexoy-
cholic acid treatment has been maintained continuously. In
2002, she was well and attended for routine annual review.
On this occasion, her routine ultrasound examination of the
hepatic system revealed an additional prominence of the
left lobe of the liver, suggesting the diagnosis of multifocal
hepatocellular carcinoma. This prompted an urgent referral
to the hepatology services. There were no other risk factors
for cirrhosis including minimal alcohol consumption, and auropean Cystic Fibrosis Society.
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Serological markers for viral hepatitis (A, B and C) were
negative, as were markers for autoimmune and metabolic
liver disease. It was accepted that her cirrhosis was purely
due to cystic fibrosis.2. Investigations
Further investigations revealed a serum concentration
alpha-fetoprotein of 969 kU/l.
A CT scan showed two 4-cm-diameter lesions in the right
lobe of her liver associated with a cirrhotic liver.
An ultrasound scan showed again two right liver lobe
lesions consistent with hepatocellular carcinoma.
An MRI scan demonstrated the two lesions highly
suggestive of a hepatocellular carcinoma (Fig. 1).3. Progress
Hepatic angiography was booked, however, prior to
this; it transpired that the patient was pregnant, which
contraindicated this procedure. A pelvic ultrasound scan
revealed a 6-week-old intrauterine fetus. An ultrasound
guided liver biopsy of the lesion was performed in order to
make a histological diagnosis. The histology showed a
poorly differentiated adenocarcinoma, consistent with a
hepatocellular carcinoma on a background of cirrhotic
liver due to cystic fibrosis. Unfortunately, the size of this
lady’s hepatocellular carcinomas contraindicated liver
transplantation. To be potentially curable by transplanta-
tion, the tumour size would need to be either less than 5Fig. 1.cm (single tumour) or up to three tumours less than 3 cm
diameter. She was therefore referred to a national hepatol-
ogy centre for local ablation therapy in the hope of
slowing tumour growth.4. Discussion
Cystic fibrosis liver disease (CFLD) is the second most
common cause of death in patients with CF [1]. The
pathogenesis is due to the presence of an abnormal cystic
fibrosis transmembrane conductance regulator (CFTR)
expressed on the biliary epithelium [2]. The overall effect
of the abnormal CFTR is to produce a thicker and less
alkaline bile that accumulates in the biliary tree. Fibrosis is
thought to lead on to cirrhosis over a period of years, a
process which is usually asymptomatic [3]. The prevalence
of liver disease among CF patients ranges between 2% and
37% [4–6], depending on the population studied and on the
definition of liver disease [7]. Macronodular liver cirrhosis
with portal hypertension occurs maximally in 10% of
patients with CFLD [8] and peaks in adolescence. It is
thought to progress slowly through adulthood and is treated
definitively by liver transplantation [3]. The use of urso-
deoxycholic acid improves the biochemical markers of
CFLD and it may slow its progression [9]. CFLD is
invariably associated with pancreatic insufficiency [10]
and with more severe mutations such as Delta F508 as in
this case [11].
Hepatocellular carcinoma is the most common primary
tumour on the globe [12] and the number of new cases is
increasing [13]. The main aetiological factors are chronic
hepatitis B and C infections which account for over 80% of
cases worldwide [14]. Other aetiological factors include
alcohol and autoimmune diseases which produce liver
cirrhosis. Males are predominantly affected, with a 2:3
female/male ratio [13]. This is the first documented case
to our knowledge that describes hepatocellular carcinoma
associated with cirrhosis as a result of CF. Unfortunately,
her tumour was too large for potential curative liver trans-
plantation and as such, her prognosis remains poor [15]. At
the time of writing, she remains well in herself with a 24-
week fetus growing normally. The patient has decided to
progress with her pregnancy. The laser therapy has been
well tolerated.
Increased risk of cancer has previously been described
in CF in both a North American and European cohort. Of
particular note was the increased risk of gastrointestinal
tract malignancy [16]. It is our concern that as CF adults’
life expectancy increases and more patients survive with
macronodular cirrhosis, hepatocellular carcinoma may be-
come an increasingly recognised complication. It is notable
that this patient had long established liver disease with
cirrhosis for at least 10 years. The annual liver ultrasound
in the previous year did not reveal malignancy, but by the
time of diagnosis, the tumour was too large to consider
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our practice such that all patients with CF and macro-
nodular cirrhosis will now have ultrasound scanning of
their liver biannually and will have yearly control of serum
concentration alpha-fetoprotein.References
[1] Genyk YS, Quiros JA, Jabbour N, Selby RR, Thomas DW. Liver
transplantation in cystic fibrosis. Curr Opin Pulm Med 2001;7(6):
441–7.
[2] Kinnman N, Lindblad A, Housset C, Buentke E, Scheynius A, Strand-
vik B, et al. Expression of cystic fibrosis transmembrane conductance
regulator in liver tissue from patients with cystic fibrosis. Hepatology
2000;32(2):334–40.
[3] Diwakar V, Pearson L, Beath S. Liver disease in children with cystic
fibrosis. Paediatr Respir Rev 2001;2(4):340–9.
[4] Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D,
Padoan R, et al. Liver disease in cystic fibrosis: a prospective study
on incidence, risk factors, and outcome. Hepatology 2002;36(6):
1374–82.
[5] Scott-Jupp R, Lama M, Tanner MS, Prevalence of liver disease in
cystic fibrosis. Arch Dis Child June 66 (6) 698–701.
[6] Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A,
et al. Analysis of risk factors for the development of liver disease
associated with cystic fibrosis. J Pediatr 1994;124(3):393–9.[7] Lindblad A, Glaumann H, Strandvik B. Natural history of liver dis-
ease in cystic fibrosis. Hepatology 1999;30(5):1151–8.
[8] Noble-Jamieson G, Barnes N, Jamieson N, Friend P, Calne R. Liver
transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med
1996;89(Suppl. 27):31–7.
[9] Lindblad A, Glaumann H, Strandvik B. A two-year prospective study
of the effect of ursodeoxycholic acid on urinary bile acid secretion
and liver morphology in cystic fibrosis-associated liver disease. Hep-
atology 1998;27:166–74.
[10] Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M,
et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF):
comparison of major disease manifestations between patients with
different classes of mutations. Pediatr Pulmonol 2001;31(1):1–12.
[11] Nousia-Arvanitakis S, Fotoulaki M, Economou H, Xefteri M, Galli-
Tsinopoulou A. Long-term prospective study of the effect of urso-
deoxycholic acid on cystic fibrosis-related liver disease 5. J Clin
Gastroenterol 2001;32(4):324–8.
[12] Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma.
J Clin Gastroenterol 2002;35(5 Suppl. 2):S86–91.
[13] Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A,
Castagnetta LA. Epidemiology, risk factors, and natural history of
hepatocellular carcinoma. Ann NY Acad Sci 2002;963:13–20.
[14] Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepa-
tocellular carcinoma 45. Can J Gastroenterol 2000;14(8):703–9.
[15] Hemming AW, Nelson DR, Reed AI. Liver transplantation for hepa-
tocellular carcinoma. Minerva Chir 2002;57(5):575–85.
[16] Neglia A, et al. The risk of cancer among patients with cystic fibrosis.
N Engl J Med 1995;332:494–9.
